PAP
NXTC icon

Persistent Asset Partners’s NextCure NXTC Stock Holding History

Persistent Asset Partners’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17K Buy
+1,981
New +$14.6K ﹤0.01% 780

Other funds holding NXTC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Persistent Asset Partners's NXTC Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in NextCure (NXTC) in Q2 2026: 1,981 shares worth $3.17K. The stake represents ﹤0.01% of the portfolio and ranks #780 among its holdings.

17 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Persistent Asset Partners held 1,981 shares of NextCure worth $3.17K as of Q2 2026.
  • NextCure was a new Persistent Asset Partners position in Q2 2026.
  • NextCure made up ﹤0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #780 holding.
  • 17 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.